ARTICLE | Company News

Emergent BioSolutions, Centers for Disease Control and Prevention infectious news

July 26, 2010 7:00 AM UTC

The CDC modified Emergent's procurement contract for its BioThrax anthrax vaccine, increasing the number of BioThrax doses that Emergent can deliver into the Strategic National Stockpile during 2010. As a result, Emergent raised its 2010 revenue guidance to $275-$300 million from $235-$255 million. The CDC contract expires in 3Q11; however, the company is in negotiations for a new three-year contract, which it hopes to disclose by year end. ...